Before a drug goes to market, its efficacy, safety, and mechanism of action (MOA) must be thoroughly evaluated. Under the BioMice subbrand, Biocytogen offers a full spectrum of animal model solutions to support drug discovery and development. Our services include custom gene editing, humanized mouse models, genetically modified animal models, and human cell lines for basic and preclinical research. In addition, we provide comprehensive in vivo, ex vivo, and in vitro pharmacology services. These integrated solutions help researchers efficiently advance their projects from target identification to IND submission.
At Biocytogen, we deliver cutting-edge humanized and genetically modified mouse models and top-tier preclinical services to accelerate innovative drug development. Our solutions enable global partners to achieve breakthroughs across diverse therapeutic areas.
Our innovative portfolio includes 1000+ drug target humanized mouse models, 800+ knockout mouse models, and various other genetically modified mouse models and rat models for basic research and drug evaluation.
Learn More
We have successfully supported pharmaceutical and biotech partners by providing tailored preclinical efficacy and toxicity studies for a variety of biologics, leveraging humanized mouse models and other animal models to deliver actionable insights.
Learn More
Using our proprietary gene-editing technologies, we create custom humanized mouse models, rat models, and cell lines, tailored to the specific needs of research and drug discovery programs.
Learn More
Our AAALAC-accredited animal facilities provide breeding, cryopreservation, and rederivation services, ensuring the production of high-quality humanized and other specialized mouse models for preclinical research.
Learn More
We offer a broad range of disease models based on wild-type and humanized mouse models, along with integrated service solutions to advance drug development across multiple therapeutic areas.
Biocytogen's comprehensive pharmacology platforms and a wide range of animal models, offers global clients the one-stop solutions for various drug modalities, including monoclonal antibodies, bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), peptides, tumor vaccines, small molecules, CAR-T cell therapy, and oncolytic viruses.
Biocytogen provides customized solutions featuring ready-to-use mouse models and comprehensive research services, advancing therapeutic development across diverse disease areas such as oncology, autoimmune and inflammatory diseases, cardiovascular and cerebrovascular diseases, metabolic disorders, neuroscience, ophthalmology, and more.
Biocytogen operates world-class, AAALAC-accredited SPF facilities totaling approximately 55,000 square meters, with a capacity of 150,000 cages and an annual supply capacity of 800,000 gene-edited mice, located in Haimen, Jiangsu, and Daxing, Beijing, China, as well as a smaller facility in Boston, U.S.
With a wide range of animal strains, large-scale supply capabilities, and high-quality services, BioMice have been recognized by numerous research institutes and biotech/biopharmaceutical companies worldwide, including all of the top 10 multinational corporations.
For more information about how BioMice products and services can support your research, please contact us today.
Contact UsEurope
North America
Asia
